南模生物股价跌5.82%，天弘基金旗下1只基金位居十大流通股东，持有37.74万股浮亏损失120.78万元

Group 1 - The core point of the news is that Nanmo Biotechnology experienced a decline of 5.82% in its stock price, reaching 51.80 yuan per share, with a trading volume of 30.42 million yuan and a turnover rate of 0.74%, resulting in a total market capitalization of 4.039 billion yuan [1] - Nanmo Biotechnology, established on September 20, 2000, and listed on December 28, 2021, specializes in the research, production, sales, and related technical services of genetically modified animal models [1] - The revenue composition of Nanmo Biotechnology includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other supplementary services (0.91%) [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biotechnology, holding 377,400 shares, which accounts for 0.48% of the circulating shares, with an estimated floating loss of approximately 1.2078 million yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, achieving a year-to-date return of 16.59% and a one-year return of 56.11% [2] - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 48.08% and the worst being 47.47% [3]